New Dual-Action drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06911489
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-phase trial is testing two new drugs for people with advanced solid tumors that have not responded to standard treatments. The first drug helps doctors see tumors on a PET scan, and the second delivers targeted radiation to destroy cancer cells. The study will check safety, find the right dose, and see if the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.